Nesiritide may be beneficial in the prevention of renal dysfunction after CABG
Feb 10, 2007 - 9:47:01 AM
, Reviewed by: Dr. Rashmi Yadav
|
|
|
"These kidney, safety and mortality findings from the NAPA trial are encouraging as they suggest that nesiritide may provide important clinical benefit to heart failure patients undergoing CABG surgery with cardiopulmonary bypass."
|
By Wayne State University,
[RxPG]
 |
| A statistically significant number of patients who received Natrecor(R) and recovered better than those who received the placebo. |
Natrecor(R) (nesiritide) may be beneficial in the prevention of renal dysfunction after coronary artery bypass grafting requiring cardiopulmonary bypass, suggests "Effects of Perioperative Nesiritide in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery: The NAPA Trial." The study will be published in the February 13 issue of the Journal of the American College of Cardiology.
Patients in the study were experiencing heart failure and had limited treatment options. Those taking Natrecor(R) had improved outcomes, including shorter hospital stays and a statistically significant decrease in mortality rate after 180 days than patients receiving the placebo, determined the study sponsored by Scios Inc.
"We discovered a statistically significant number of patients who received Natrecor(R) and recovered better than those who received the placebo," said principal investigator Robert M. Mentzer, Jr., M.D., F.A.C.C. Dr. Mentzer is dean of the medical school at Wayne State University, senior advisor to the president for medical affairs and is a professor in the Division of Cardiothoracic Surgery, Department of Surgery. He added, "Patients on nesiritide had significantly greater urine output within 24 hours after surgery and overall better preservation of kidney functioning during hospitalization as well as two weeks after surgery."
The prospective, multi-center, double-blind Phase 2 NAPA (Nesiritide Administered Peri-Anesthesia in Patients Undergoing Cardiac Surgery) trial of 279 randomized patients was designed to determine the role Natrecor(R) (nesiritide) may play in the management of patients with left ventricular dysfunction undergoing coronary artery bypass grafting (CABG) that required cardiopulmonary bypass.
"These kidney, safety and mortality findings from the NAPA trial are encouraging as they suggest that nesiritide may provide important clinical benefit to heart failure patients undergoing CABG surgery with cardiopulmonary bypass," said Roger Mills, M.D., vice president, medical affairs at Scios. "We are assessing the design of a Phase 3 trial in cardiac surgery patients to further study this investigational use of nesiritide and will be submitting these data to the F.D.A."
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to CTVS Newsletter
|
|
|
|
About Dr. Rashmi Yadav
|
This news story has been reviewed by Dr. Rashmi Yadav before its publication on RxPG News website. Dr. Rashmi Yadav, MBBS, is a senior editor for RxPG News. In her position she is responsible for managing special correspondents and the surgery section of the website. Her areas of special interest include cardiothoracic surgery and interventional radiology.
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
|
|
Additional information about the news article
|
Dr. Mentzer conducted the research and authored the paper with Mehmet C. Oz, M.D., F.A.C.C., Division of Cardiothoracic Surgery, College of Physicians and Surgeons, Columbia University; Robert N. Sladen, M.D., F.C.C.M., Department of Anesthesiology, College of Physicians and Surgeons, Columbia University; Allen H. Graeve, M.D., F.A.C.S., Multicare Cardiothoracic Surgical Associates, Tacoma General Hospital; Robert F. Hebeler, Jr., M.D., Department of Surgery, Baylor University Medical Center; John M. Luber, Jr., M.D., F.A.C.S., Franciscan Health System Research Center, Tacoma; and Nicholas G. Smedira, M.D., F.A.C.C., Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic.
The Journal of the American College of Cardiology, a peer-reviewed journal featuring clinical and experimental reports, new diagnostic techniques, clinical reviews and editorial commentary, published online the research paper developed by medical doctors and researchers at the Wayne State University School of Medicine, Columbia University College of Physicians and Surgeons and other premier medical institutions.
About Wayne State University
With more than 1,000 students, the Wayne State University School of Medicine is the nation's third largest medical school. Together with the Wayne State University Physician Group and 13 hospital partners, the school is a leader in medical research and patient care with emphases on cancer; maternal- child health; neurosciences; and population studies and urban health. For more information, visit www.med.wayne.edu.
Wayne State University is a premier institution of higher education offering more than 350 academic programs through 11 schools and colleges to more than 33,000 students. For more information, visit www.wayne.edu.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
